Home › Funds › Affinity Asset Advisors, LLC › CYTK

Affinity Asset Advisors, LLC position in CYTK

CYTOKINETICS INC · Health Care

Affinity Asset Advisors, LLC reported holding 750,000 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$49.4M, representing 2.30% of its reported portfolio and ranking #11 among its reported holdings. Affinity Asset Advisors, LLC has disclosed CYTK holdings in 8 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)750.00K sh
Reported value held$49.43M
Portfolio Weight2.30%
First reportedQ3 2023
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Affinity Asset Advisors, LLC's CYTK position evolved

Affinity Asset Advisors, LLC first disclosed a stake in CYTK in Q3 2023 at 230,366 shares (US$6.8M). The position peaked in Q4 2025 at 800,000 shares, worth US$50.8M. Across 8 filings, Affinity Asset Advisors, LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 750,000 shares valued at US$49.4M — an increase of 200,000 shares quarter over quarter.. Notable position changes include a 50% trim in Q1 2024 (shares fell 23% over the following quarter), a 129% increase in Q4 2025 (shares rose 4% over the following quarter), a 36% increase in Q3 2026 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 230.37K $6.79M New
Q4 2023 160.00K $13.36M Reduce
Q1 2024 80.00K $5.61M Reduce
Q3 2025 350.00K $19.24M New
Q4 2025 800.00K $50.83M Add
Q1 2026 700.48K $46.17M Reduce
Q2 2026 550.00K $46.85M Reduce
Q3 2026 750.00K $49.43M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CYTK and 13F data

CYTK (CYTOKINETICS INC) is a Health Care company. 42 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CYTK

All CYTK fund holders →

FAQ

How long has Affinity Asset Advisors, LLC held CYTK?

Affinity Asset Advisors, LLC has disclosed CYTK holdings in 8 of the last 13 reported quarters, going back to Q3 2023.

What is Affinity Asset Advisors, LLC's current position in CYTK?

As of Q3 2026, Affinity Asset Advisors, LLC holds 750.00K shares of CYTK (CYTOKINETICS INC), valued at $49.43M, representing 2.30% of its reported portfolio and ranking #11.

Has Affinity Asset Advisors, LLC been buying or selling CYTK?

In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC increased its position in CYTK. The position peaked in Q4 2025 at 800.00K shares.

Which other funds hold CYTK?

Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.